(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share
…Category: State
Breaking News
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts
…